Skip to main content

Table 2 Summary table on costs and utilities for HPV-related disease

From: Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria

Parameter

Gender

Inflated values (€2014)

Utility [27, 58, 59]

- CIN 1

Female

377 € [54]

0.91

- CIN 2

Female

377 € [54]

0.87

- CIN 3 and CIS

Female

1681 € [54]

0.87

- Cervical cancer, local diseasea

Female

19,151 € [19]

0.76

- Cervical cancer, regional diseasea

Female

31,978 € [19]

0.67

- Cervical cancer, distant diseasea

Female

32,651 € [19]

0.48

- VaIN 2

Female

936 € [55]

0.87

- VaIN 3, CIS

Female

2766 € [55]

0.87

- Vaginal cancer, local diseasea

Female

16,661 € [19]

0.76

- Vaginal cancer, regional diseasea

Female

27,820 € [19]

0.67

- Vaginal cancer, distant diseasea

Female

28,406 € [19]

0.48

- Vulvar cancer, local diseasea

Female

16,661 € [19]

0.76

- Vulvar cancer, regional diseasea

Female

27,820 € [19]

0.67

- Vulvar cancer, distant diseasea

Female

28,406 € [19]

0.48

- Penile cancer, local diseasea

Male

13,597 € [19]

0.76

- Penile cancer, regional diseasea

Male

22,703 € [19]

0.67

- Penile, distant diseasea

Male

23,182 € [19]

0.48

- Anal cancer, local diseasea

Male; Female

19,534 € [19]

0.76

- Anal cancer, regional diseasea

Male; Female

32,617 € [19]

0.67

- anal cancer, distant diseasea

Male; Female

33,304 € [19]

0.48

- Head & Neck cancer, local diseasea

Male; Female

22,981 € [19]

0.76

- Head & Neck cancer, regional diseasea

Male; Female

38,373 € [19]

0.67

- Head & Neck cancer, distant diseasea

Male; Female

39,181 € [19]

0.48

- Genital warts

Male; Female

661 € [54]

0.91

- Recurrent respiratory papillomatosis

Male; Female

26,812 € [56]

0.81

  1. aDisease stages can be related to the traditional Tumour-Node-Metastasis (TNM) classification system as followed: − “Local disease” corresponds to stages I and II TNM classification, i.e., localized primary tumour; “Regional disease” corresponds to stage III TNM classification system, i.e., metastasis to regional lymph nodes; “Distant disease” corresponds to stage IV TNM classification system, i.e., distant metastatic disease